These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Listening to Provenge--what a costly cancer treatment says about future Medicare policy. Chambers JD; Neumann PJ N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004 [No Abstract] [Full Text] [Related]
3. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product. Baghdadi R Oncology (Williston Park); 2010 Sep; 24(10):881-3. PubMed ID: 21138168 [No Abstract] [Full Text] [Related]
4. Approval of provenge seen as first step for cancer treatment vaccines. Brower V J Natl Cancer Inst; 2010 Aug; 102(15):1108-10. PubMed ID: 20668267 [No Abstract] [Full Text] [Related]
10. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. Jarosławski S; Toumi M BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092 [TBL] [Abstract][Full Text] [Related]
11. Managed care considerations. A new era of advanced prostate cancer management. Muller R Manag Care; 2011 Sep; 20(9 Suppl 5):5. PubMed ID: 22043721 [No Abstract] [Full Text] [Related]
12. Is Provenge Angst a symbol or symptom of the times? Holcombe DG Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274 [No Abstract] [Full Text] [Related]
13. Two years of Provenge. Riedmann EM Hum Vaccin Immunother; 2012 Apr; 8(4):505. PubMed ID: 22832253 [No Abstract] [Full Text] [Related]
15. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer? Moyad MA Urol Nurs; 2007 Jun; 27(3):256-7. PubMed ID: 17674606 [TBL] [Abstract][Full Text] [Related]
16. The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity. Bot A Int Rev Immunol; 2010 Jun; 29(3):235-8. PubMed ID: 20521923 [No Abstract] [Full Text] [Related]
17. Cancer vaccine approval could open floodgates. Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296 [No Abstract] [Full Text] [Related]